10-Q: Sensei Biotherapeutics Reports Q2 2024 Financial Results and Clinical Trial Update

Sensei Biotherapeutics reports a net loss of $15.1 million for the first half of 2024, while providing an update on its clinical trial for SNS-101 and extending its cash runway into the fourth quarter of 2025.

Summary

• Sensei Biotherapeutics, an immuno-oncology company, reported a net loss of $15.1 million for the six months ended June 30, 2024, compared to a net loss of $19.6 million for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $52.3 million as of June 30, 2024.
• Sensei expects this cash balance to fund operations into the fourth quarter of 2025.
• Research and development expenses were $9.5 million for the first half of 2024, a decrease from $10.0 million in the first half of 2023.
• General and administrative expenses decreased to $7.0 million for the first half of 2024, down from $11.2 million in the same period of 2023.
• The company is advancing its lead product candidate, SNS-101, a conditionally active monoclonal antibody targeting VISTA, through a Phase 1/2 clinical trial.
• Initial data from the dose escalation portion of the SNS-101 trial were presented at the ASCO Annual Meeting, showing the drug was well-tolerated and demonstrated a potentially best-in-class pharmacokinetic profile.
• Patient enrollment is progressing in the dose expansion portion of the Phase 1/2 study, which is now expected to enroll 50 to 70 patients.
• Sensei plans to report initial data from the dose expansion cohorts and hold an end-of-Phase 1 meeting with the FDA by the end of 2024.
• The company has paused IND-enabling studies for its next TMAb product candidate to focus on the SNS-101 trial.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive signs in the clinical trial data and a reduction in losses, the company still faces significant financial challenges and development risks. The pause in IND-enabling studies for other product candidates is a concern.

Positives

• The company's net loss decreased compared to the same period last year.
• The company has sufficient cash to fund operations into the fourth quarter of 2025.
• SNS-101 demonstrated a favorable safety profile and promising early efficacy signals in its clinical trial.
• The company is progressing with patient enrollment in the dose expansion portion of the SNS-101 trial.
• Sensei is on track to report initial data from the dose expansion cohorts and hold an end-of-Phase 1 meeting with the FDA by the end of 2024.

Negatives

• The company continues to incur significant operating losses.
• The company has no products approved for sale and does not expect to generate revenue from product sales for at least the next several years.
• The company has paused IND-enabling studies for its next TMAb product candidate to focus on the SNS-101 trial.
• The company is dependent on third parties for manufacturing and clinical trials.

Risks

• The company will need additional funding to complete the development of its product candidates.
• The company's product candidates are in early stages of development and may not be successful.
• Clinical trials are difficult to design and implement, can be lengthy and expensive, and may not be successful.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or failures.
• The company faces significant competition in the biopharmaceutical industry.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to achieve market acceptance for its product candidates, even if approved.
• The company's intellectual property may not be adequately protected.
• The company's stock price may be volatile.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the fourth quarter of 2025. They plan to continue reviewing financial resources with the expectation that IND-enabling studies for additional TMAb product candidates will resume if they raise sufficient additional capital.

Management Comments

• The company expects to report initial data from the dose expansion cohorts of the SNS-101 trial and hold an end-of-Phase 1 meeting with the FDA by the end of 2024.
• The company has paused IND-enabling studies for its next TMAb product candidate to focus on the SNS-101 trial.

Industry Context

Sensei is operating in the competitive immuno-oncology space, where numerous companies are developing novel cancer therapies. The company's focus on conditionally active antibodies and the tumor microenvironment aligns with current trends in the field. The company is competing with other companies developing VISTA targeting antibodies.

Comparison to Industry Standards

• Sensei's cash runway into Q4 2025 is relatively short compared to some other biotech companies, which often aim for 2-3 years of funding.
• The clinical trial results for SNS-101 are promising, but the partial response rate is still early and needs to be confirmed in larger trials. Companies like Regeneron and Merck have established a high bar for efficacy in immuno-oncology.
• The company's decision to pause IND-enabling studies for other product candidates is a common strategy for smaller biotechs to focus resources, but it also carries the risk of delaying pipeline development. Companies like BioNTech and Moderna have demonstrated the value of a diverse pipeline.
• Sensei's reliance on third-party CMOs is standard in the industry, but it also introduces risks related to supply chain and manufacturing quality. Companies like Amgen and Genentech have invested heavily in their own manufacturing capabilities to mitigate these risks.

Related Party Transactions

• On May 23, 2023, the Company entered into the Apeiron Purchase Agreement with the Apeiron Parties, pursuant to which the Company agreed to purchase 4,454,248 shares of the Company's common stock from certain of the Apeiron Parties for a purchase price of $1.58 per share.
• On July 31, 2023, the Company entered into the Cambrian Purchase Agreement, pursuant to which the Company agreed to repurchase 1,587,302 shares of its common stock from Cambrian, a beneficial owner of more than 5% of the Company's outstanding shares of common stock, at a purchase price of $1.26 per share.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial situation and strategic decisions.
• Patients may benefit from the development of new cancer therapies, but clinical trials carry inherent risks.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Continue patient enrollment in the dose expansion portion of the Phase 1/2 study of SNS-101.
• Report initial data from the dose expansion cohorts of the SNS-101 trial.
• Hold an end-of-Phase 1 meeting with the FDA by the end of 2024.
• Continue preclinical work on TMAb product candidates.
• Review financial resources and potentially resume IND-enabling studies for additional TMAb product candidates if sufficient capital is raised.

Key Dates

Keywords

immuno-oncology, biotherapeutics, clinical trial, SNS-101, VISTA, TMAb, cancer therapy, monoclonal antibody, drug development, financial results